The stock of Cincinnati Bell Inc. (NYSE:CBB) hit a new 52-week low and has $16.14 target or 7.00% below today’s $17.35 share price. The 5 months bearish chart indicates high risk for the $730.98M company. The 1-year low was reported on Apr, 5 by Barchart.com. If the $16.14 price target is reached, the company will be worth $51.17 million less. The stock decreased 0.86% or $0.15 during the last trading session, reaching $17.35. About 712,367 shares traded or 122.88% up from the average. Cincinnati Bell Inc. (NYSE:CBB) has declined 17.84% since August 29, 2016 and is downtrending. It has underperformed by 26.09% the S&P500.
Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development platform, focused on neurological and endocrine based diseases and disorders. The company has market cap of $3.54 billion. The Company’s three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. It currently has negative earnings. The Company’s product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia.
Since January 3, 2017, it had 3 buys, and 1 sale for $899,910 activity. The insider Fox Leigh R. bought 500 shares worth $9,420. Another trade for 1,000 shares valued at $19,100 was bought by Kaiser Andrew R.. Another trade for 40,000 shares valued at $947,200 was sold by Torbeck Theodore H..
Cincinnati Bell Inc., along with its subsidiaries, provides diversified telecommunications and technology services. The company has market cap of $730.98 million. The Firm operates through two divisions: Entertainment and Communications, and IT Services and Hardware. It has a 7.99 P/E ratio. Through its Entertainment and Communications segment, the Company provides high-speed data, video and voice solutions to clients and businesses over fiber network and a legacy copper network.
Analysts await Cincinnati Bell Inc. (NYSE:CBB) to report earnings on May, 4. They expect $0.02 EPS, down 60.00% or $0.03 from last year’s $0.05 per share. CBB’s profit will be $842,628 for 216.88 P/E if the $0.02 EPS becomes a reality. After $0.01 actual EPS reported by Cincinnati Bell Inc. for the previous quarter, Wall Street now forecasts 100.00% EPS growth.
Among 2 analysts covering Cincinnati Bell (NYSE:CBB), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Cincinnati Bell had 4 analyst reports since August 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, October 6 by Gabelli. Raymond James downgraded the shares of CBB in report on Tuesday, December 6 to “Underperform” rating. The rating was maintained by Gabelli on Friday, August 21 with “Buy”.
Investors sentiment decreased to 0 in 2016 Q4. Its down 0.88, from 0.88 in 2016Q3. It dived, as 127 investors sold Cincinnati Bell Inc. shares while 1 reduced holdings. 0 funds opened positions while 0 raised stakes. 4,477 shares or 100.00% less from 162.57 million shares in 2016Q3 were reported. Fifth Third Retail Bank stated it has 0% of its portfolio in Cincinnati Bell Inc. (NYSE:CBB). Alphamark Advisors Ltd reported 1,080 shares stake.
Since January 1, 0001, it had 0 buys, and 29 selling transactions for $3.66 million activity.
Ratings analysis reveals 100% of Neurocrine Biosci’s analysts are positive. Out of 8 Wall Street analysts rating Neurocrine Biosci, 8 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $62 while the high is $96. The stock’s average target of $74.80 is 79.25% above today’s ($41.73) share price. NBIX was included in 9 notes of analysts from August 18, 2015. Piper Jaffray maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) rating on Thursday, October 8. Piper Jaffray has “Overweight” rating and $96 target. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) earned “Outperform” rating by BMO Capital Markets on Thursday, April 7. The firm earned “Perform” rating on Tuesday, November 22 by Oppenheimer. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Tuesday, October 18 by Needham. As per Thursday, November 3, the company rating was initiated by Deutsche Bank. H.C. Wainwright initiated the shares of NBIX in report on Wednesday, June 29 with “Buy” rating. Leerink Swann maintained Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Monday, October 12 with “Outperform” rating. Jefferies reinitiated the stock with “Buy” rating in Tuesday, August 18 report. The rating was upgraded by Oppenheimer to “Outperform” on Friday, January 27.
Perceptive Advisors Llc holds 9.13% of its portfolio in Neurocrine Biosciences, Inc. for 3.32 million shares. Great Point Partners Llc owns 750,000 shares or 5.96% of their US portfolio. Moreover, Bb Biotech Ag has 4.52% invested in the company for 3.15 million shares. The California-based Venbio Select Advisor Llc has invested 4.23% in the stock. Pyrrho Capital Management Lp, a New York-based fund reported 55,204 shares.
About 1.32 million shares traded or 56.36% up from the average. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has declined 12.35% since August 29, 2016 and is downtrending. It has underperformed by 20.60% the S&P500.
Analysts await Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to report earnings on May, 4. They expect $-0.62 earnings per share, down 181.82% or $0.40 from last year’s $-0.22 per share. After $-0.51 actual earnings per share reported by Neurocrine Biosciences, Inc. for the previous quarter, Wall Street now forecasts 21.57% negative EPS growth.
